Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
A small, single-centre in-vitro study with a null finding; the design is sound but the sample is limited (n=15) and the scope restricted to three media conditions, leaving open whether other culture or earlier developmental stages affect sperm DNA methylation.
This is a comprehensive narrative review synthesizing mechanistic and preclinical findings on deubiquitinases in breast cancer, with no clinical trial data, prospective validation, or regulatory approval to support practice change.
A scoping review synthesizing preclinical and mechanistic evidence on Sp1 in OSCC with scRNA-seq analysis, raising translational questions but reporting no clinical trials or human efficacy data.
Cell line study identifying a mechanistic link between AR CAG repeat polymorphism and metabolic reprogramming; lacks in vivo validation, patient outcome data, or clinical endpoint evidence.
In vitro mechanistic study in a single TNBC cell line suggesting synergy between two agents, lacking any in vivo validation, patient data, or clinical trial evidence to support therapeutic application.
This is a mechanistic review proposing a novel conceptual framework linking PAH chronotoxicity to cancer via circadian dysregulation; it raises questions rather than testing them empirically.
This is a narrative review synthesizing mechanistic concepts and therapeutic rationales without reporting primary empirical findings, clinical trial data, or comparative evidence from original research.